Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRAS | P01112 | 8/20 | 0.60 |
| ▸ | ESR1 | P03372 | 8/20 | 0.60 |
| ▸ | ESR2 | Q92731 | 8/20 | 0.60 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.54 |
| ▸ | HTR2C | P28335 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.43 |
| ▸ | PLD2 | O14939 | 1/20 | 0.42 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | GHSR | Q92847 | 2/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | NHERF1 | O14745 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5889571 | 0.88 | HRAS (0.59) | HRASESR1ESR2HDAC2PLD2 | |
| SCHEMBL6779947 | 0.85 | HRAS (0.52) | HRASESR1ESR2HRH4HRH3 | |
| SCHEMBL5889566 | 0.85 | HRAS (0.53) | HRASESR1ESR2HRH4HRH3 | |
| SCHEMBL5889545 | 0.83 | HRAS (0.53) | HRASESR1ESR2HDAC2HDAC8 | |
| SCHEMBL5889560 | 0.83 | HRAS (0.54) | HRASESR1ESR2HDAC2PLD2 | |
| SCHEMBL5889831 | 0.82 | NHERF1 (0.53) | HRASESR1ESR2HRH3PLD2 | |
| SCHEMBL5889578 | 0.82 | HTR2C (0.61) | HRASESR1ESR2HRH4HRH3 | |
| SCHEMBL5889480 | 0.81 | KDM4E (0.49) | HRASESR1ESR2PLD2PLD1 | |
| SCHEMBL5889693 | 0.79 | HRH4 (0.56) | HRASESR1ESR2HRH4HRH3 | |
| SCHEMBL15223792 | 0.77 | HRH4 (0.65) | HRH4HRH3HTR2CSYKGHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7064218-B2 | Aromatic compounds and poly(oxyalkylene) containing aromatic compounds possessing antibacterial, antifungal or antitumor activity | GENELABS TECHNOLOGIES, INC. (US) | 2006-06-20 | — | — | US | disclosed |
| US-6906103-B2 | Compounds possessing antibacterial, antifungal or antitumor activity | GENELABS TECHNOLOGIES, INC. (US) | 2005-06-14 | — | — | US | disclosed |
| US-6849713-B2 | Compounds possessing antibacterial, antifungal or antitumor activity | GENELABS TECHNOLOGIES, INC. (US) | 2005-02-01 | — | — | US | disclosed |
| US-20030212113-A1 | Novel aromatic compounds and poly(oxyalkylene) containing aromatic compounds possessing antibacterial, antifungal or antitumor activity | GLAXOSMITHKLINE LLC | 2003-11-13 | — | — | US | disclosed |
| WO-2003057212-A1 | POLYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL, ANTIFUNGAL OR ANTITUMOR ACTIVITY | GENELABS TECHNOLOGIES, INC. (US) | 2003-07-17 | — | — | WO | disclosed |
| US-20030119749-A1 | Novel compounds possessing antibacterial, antifungal or antitumor activity | SMITHKLINE BEECHAM CORPORATION | 2003-06-26 | — | — | US | disclosed |
| EP-1294713-A2 | COMPOUNDS POSSESSING ANTIBACTERIAL, ANTIFUNGAL OR ANTITUMOR ACTIVITY | GENELABS TECHNOLOGIES, INC. (US) | 2003-03-26 | — | — | EP | disclosed |
| US-20020037856-A1 | Novel compounds possessing antibacterial, antifungal or antitumor activity | GENELABS TECHNOLOGIES, INC. | 2002-03-28 | — | — | US | disclosed |
| WO-2002000650-A2 | NOVEL COMPOUNDS POSSESSING ANTIBACTERIAL, ANTIFUNGAL OR ANTITUMOR ACTIVITY | GENELABS TECHNOLOGIES, INC. (US) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119749-A1 | Novel compounds possessing antibacterial, antifungal or antitumor activity | CYP51A1, MCL1, ERG28 | HRAS 402/4885ESR1 4097/4885ESR2 3377/4885 |
| US-20020037856-A1 | Novel compounds possessing antibacterial, antifungal or antitumor activity | CYP51A1, MCL1, ERG28 | HRAS 402/4885ESR1 4097/4885ESR2 3377/4885 |
| US-20030212113-A1 | Novel aromatic compounds and poly(oxyalkylene) containing aromatic compounds possessing antibacterial, antifungal or antitumor activity | TYR, CYP51A1, ODC1 | HRAS 1040/4885ESR1 4541/4885ESR2 4085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.